New combo therapy shows promise for incurable liver cancer
Disease control
Recruiting now
This study tests whether adding immunotherapy (camrelizumab) and a targeted drug (apatinib) to a standard liver cancer treatment called TACE can help people with advanced liver cancer live longer without their cancer growing. About 101 adults with liver cancer that cannot be remo…
Phase: PHASE3 • Sponsor: Guohui Xu • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC